Written Question·Department of Health and Social Care·UIN 61301

Alzheimer's Disease: Drugs

Tabled: 19 June 2025

Answered: 25 June 2025

Named Day

Question

Mr Andrew Snowden

To ask the Secretary of State for Health and Social Care, if he will publish the cost-benefit modelling for the prescription of (a) donanemab and (b) lecanemab for patients with early-stage Alzheimer’s disease.

Answer

Karin Smyth

The National Institute for Health and Care Excellence has published the company’s evidence submission, which includes the company’s evidence on costs and benefits, and the external assessment group report, which assesses the company’s evidence submission ...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 61301) →